{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:01:31Z","timestamp":1784599291797,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Basic Public Welfare Research Project of Wenzhou Science and Technology Bureau","award":["No. Y20240803"],"award-info":[{"award-number":["No. Y20240803"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-026-04354-4","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T02:24:21Z","timestamp":1779416661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A rare immune-related adverse event of pleural effusion after tislelizumab for non-small cell lung cancer: a case report and literature review"],"prefix":"10.1186","volume":"26","author":[{"given":"Meibin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjian","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"4354_CR1","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. JAMA Oncol. 2018;4:374\u20138.","journal-title":"JAMA Oncol"},{"key":"4354_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jtho.2022.09.217","volume":"18","author":"C Zhou","year":"2023","unstructured":"Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, et al. Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial. J Thorac Oncol. 2023;18:93\u2013105.","journal-title":"J Thorac Oncol"},{"key":"4354_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s12890-023-02755-3","volume":"23","author":"A Daei Sorkhabi","year":"2023","unstructured":"Daei Sorkhabi A, ZareDini M, Fazlollahi A, Sarkesh A, Naseri A, Mousavi SE, et al. The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials. BMC Pulm Med. 2023;23:495.","journal-title":"BMC Pulm Med"},{"key":"4354_CR4","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","volume":"19","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P, et al. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial. J Thorac Oncol. 2024;19:1073\u201385.","journal-title":"J Thorac Oncol"},{"key":"4354_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","volume":"13","author":"D Yue","year":"2025","unstructured":"Yue D, Wang W, Liu H, Chen Q, Chen C, Liu L, et al. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial. Lancet Respir Med. 2025;13:119\u201329.","journal-title":"Lancet Respir Med"},{"key":"4354_CR6","doi-asserted-by":"publisher","first-page":"1190491","DOI":"10.3389\/fonc.2023.1190491","volume":"13","author":"L Huo","year":"2023","unstructured":"Huo L, Wang C, Ding H, Shi X, Shan B, Zhou R, et al. Severe thyrotoxicosis induced by tislelizumab: a case report and literature review. Front Oncol. 2023;13:1190491.","journal-title":"Front Oncol"},{"key":"4354_CR7","first-page":"100156","volume":"2","author":"CI Shen","year":"2021","unstructured":"Shen CI, Yeh YC, Chiu CH. Progressive Pleural Effusion as an Immune-Related Adverse Event in NSCLC: A Case Report. JTO Clin Res Rep. 2021;2:100156.","journal-title":"JTO Clin Res Rep"},{"key":"4354_CR8","first-page":"3087","volume":"71","author":"S Zierold","year":"2022","unstructured":"Zierold S, Akcetin LS, Gresser E, Maier AM, K\u00f6nig A, Kramer R, et al. Checkpoint-inhibitor Induc Polyserositis Edema. Cancer Immunol Immunother. 2022;71:3087\u201392.","journal-title":"Checkpoint-inhibitor Induc Polyserositis Edema"},{"key":"4354_CR9","doi-asserted-by":"publisher","first-page":"1138483","DOI":"10.3389\/fimmu.2023.1138483","volume":"14","author":"X Guo","year":"2023","unstructured":"Guo X, Chen S, Wang X, Liu X. Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies. Front Immunol. 2023;14:1138483.","journal-title":"Front Immunol"},{"key":"4354_CR10","doi-asserted-by":"crossref","unstructured":"Xie XH, Shen PX, Wu JH, Qiu GH, Lin XQ, Xie ZH et al. Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report. Hum Vaccin Immunother. 2023;19:2240689.","DOI":"10.1080\/21645515.2023.2240689"},{"key":"4354_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40425-016-0185-2","volume":"4","author":"BC Kolla","year":"2016","unstructured":"Kolla BC, Patel MR. Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases. J Immunother Cancer. 2016;4:80.","journal-title":"J Immunother Cancer"},{"key":"4354_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Ch\u00e1vez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat reviews Disease primers. 2020;6:38.","journal-title":"Nat reviews Disease primers"},{"key":"4354_CR13","doi-asserted-by":"crossref","unstructured":"Ebinama U, Sheshadri A, Anand K, Swaminathan I. Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance. J immunotherapy precision Oncol. 2023;6:177-84.","DOI":"10.36401\/JIPO-22-38"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04354-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04354-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04354-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:07:01Z","timestamp":1784596021000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04354-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4354"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04354-4","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"8 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies involving humans were approved by the Ethics Committee of Wenzhou Central Hospital (approval No. 2024\u2013K209). Clinical trial number: not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent has been obtained from the patient to publish this paper.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"323"}}